CPX-351 in Patients With Newly Diagnosed AML at High Risk for Induction Mortality: Initial Phase II Results

Slideset - Preliminary findings demonstrate that the CPX-351 liposomal formulation of cytarabine:daunorubicin is both safe and active at reduced and higher doses in patients with AML at high risk for death during induction chemotherapy.
Source: Clinical Care Options Leukemia - Category: Hematology Source Type: research